Nurix Therapeutics Inc’s filing revealed that its Chief Financial Officer van Houte Hans unloaded Company’s shares for reported $70243.0 on May 02 ’25. In the deal valued at $11.33 per share,6,198 shares were sold. As a result of this transaction, van Houte Hans now holds 33,724 shares worth roughly $0.33 million.
Then, JOHANNES VAN HOUTE bought 6,198 shares, generating $69,170 in total proceeds.
Before that, Hansen Gwenn sold 3,377 shares. Nurix Therapeutics Inc shares valued at $38,841 were divested by the Chief Scientific Officer at a price of $11.50 per share. As a result of the transaction, Hansen Gwenn now holds 61,516 shares, worth roughly $0.6 million.
Leerink Partners initiated its Nurix Therapeutics Inc [NRIX] rating to a Market perform in a research note published on March 17, 2025; the price target was $16. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. BMO Capital Markets began covering NRIX with “an Outperform” recommendation on December 06, 2024. UBS started covering the stock on October 24, 2024. It rated NRIX as “a Buy”.
Price Performance Review of NRIX
On Tuesday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock jump 0.51% to $9.77. Over the last five days, the stock has gained 2.73%. Nurix Therapeutics Inc shares have fallen nearly -48.14% since the year began. Nevertheless, the stocks have fallen -39.35% over the past one year. While a 52-week high of $29.56 was reached on 01/27/25, a 52-week low of $8.18 was recorded on 04/10/25. SMA at 50 days reached $10.84, while 200 days put it at $18.73.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 9.63, which if violated will result in even more drops to 9.49. On the upside, there is a resistance level at 9.96. A further resistance level may holdings at 10.14. The Relative Strength Index (RSI) on the 14-day chart is 43.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.85%. Stochastics %K at 43.88% indicates the stock is a holding.
The most recent change occurred on October 11, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $41 price target.
